0.9303

0.61% -0.0057

Jasper Therapeutics Inc (JSPR)

Overview News Price History Option Chain Financials Discussions Forecast

Jasper Therapeutics Inc stock is traded at $0.9303, with a volume of 222.68K. It is down -0.61% in the last 24 hours and up +16.29% over the past month. Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.

Previous Close:

$0.936

Open:

$0.9398

24h Volume:

222.68K

Relative Volume:

0.48

Market Cap:

$26.05M

Revenue:

Net Income/Loss:

$-75.80M

P/E Ratio:

-0.2022

EPS:

-4.6004

Net Cash Flow:

$-77.17M

1W Performance:

+10.96%

1M Performance:

+16.29%

6M Performance:

-59.20%

1Y Performance:

-82.71%

1-Day Range:

$0.9199

$0.9632

1-Week Range:

$0.8488

$0.9879

52-Week Range:

$0.623

$7.19

Jasper Therapeutics Inc Stock (JSPR) Company Profile

Name

Jasper Therapeutics Inc

Sector

Healthcare (1113)

Industry

Biotechnology (622)

Phone

(650) 549-1400

Address

2200 BRIDGE PKWY SUITE #102, REDWOOD CITY

Employee

Twitter

Next Earnings Date

2026-05-11

Latest SEC Filings

JSPR's Discussions on Twitter

Compare JSPR vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
JSPR Jasper Therapeutics Inc	0.9303	26.05M	0	-75.80M	-77.17M	-4.6004
VRTX Vertex Pharmaceuticals Inc	423.92	107.83B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	701.42	73.54B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	783.50	48.72B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	296.11	39.51B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	293.86	32.66B	5.36B	287.73M	924.18M	2.5229

Jasper Therapeutics Inc Stock (JSPR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-23-26	Resumed	UBS	Neutral
Jan-13-26	Initiated	Rodman & Renshaw	Buy
Jul-08-25	Downgrade	BMO Capital Markets	Outperform → Market Perform
Jul-08-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Jul-07-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jul-07-25	Downgrade	William Blair	Outperform → Mkt Perform
Feb-13-25	Initiated	UBS	Buy
Dec-06-24	Initiated	BMO Capital Markets	Outperform
Sep-09-24	Initiated	JMP Securities	Mkt Outperform
Jul-08-24	Initiated	BTIG Research	Buy
Jun-27-24	Initiated	Stifel	Buy
May-06-24	Initiated	H.C. Wainwright	Buy
Apr-03-24	Initiated	Evercore ISI	Outperform
Mar-28-24	Initiated	RBC Capital Mkts	Outperform
Mar-18-24	Initiated	TD Cowen	Outperform
Aug-11-23	Initiated	CapitalOne	Overweight
Feb-28-22	Initiated	Cantor Fitzgerald	Overweight
Nov-08-21	Initiated	Credit Suisse	Outperform
Oct-21-21	Initiated	William Blair	Outperform
Oct-20-21	Initiated	BMO Capital Markets	Outperform
Oct-13-21	Initiated	Oppenheimer	Outperform

View All

Jasper Therapeutics Inc Stock (JSPR) Latest News

Apr 30, 2026

Why UBS started Jasper Therapeutics (JSPR) at neutral despite progress in briquilimab - MSN

Apr 17, 2026

Apr 16, 2026

Acute Myeloid Leukemia Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | SystImmune, Jasper Therapeutics, Chimerix, Akeso Biopharma, Syros Pharma, TC Biopharm - Barchart.com

Apr 16, 2026

Apr 09, 2026

Will Jasper Therapeutics (JSPR) Stock Fall Further | Price at $0.78, Up 10.73%Real Trader Insights - Newser

Apr 09, 2026

Apr 08, 2026

What is the biggest uncertainty for Jasper Therapeutics (JSPR) Stock | Price at $0.67, Up 0.87%Theta Decay - Newser

Apr 08, 2026

Apr 07, 2026

Evercore ISI Lowers its Price Target on Jasper Therapeutics (JSPR) to $7 - Insider Monkey

Apr 07, 2026

JSPR Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Apr 07, 2026

Apr 03, 2026

Analysts Offer Insights on Healthcare Companies: Jasper Therapeutics (JSPR), Alto Neuroscience, Inc. (ANRO) and Viridian Therapeutics (VRDN) - The Globe and Mail

Apr 03, 2026

Apr 02, 2026

12 Health Care Stocks Moving In Thursday's After-Market SessionBullfrog AI Hldgs (NASDAQ:BFRG), CDT Eq - Benzinga

Apr 02, 2026

UBS Maintains Jasper Therapeutics(JSPR.US) With Hold Rating, Maintains Target Price $1.5 - Moomoo

Apr 02, 2026

Apr 01, 2026

Jasper Therapeutics price target lowered to $7 from $12 at Evercore ISI - TipRanks

Apr 01, 2026

Citizens reiterates Jasper Therapeutics stock rating on CEO change By Investing.com - Investing.com Australia

Apr 01, 2026

Citizens reiterates Jasper Therapeutics stock rating on CEO change - Investing.com

Apr 01, 2026

Jasper Therapeutics’ Deep Cuts May Backfire: Analyst Warns Downsizing Could Undermine Briquilimab Strategy and Cash Runway - TipRanks

Apr 01, 2026

Mar 31, 2026

Jasper Therapeutics stock gains 5% on clinical progress despite Q4 loss - Investing.com India

Mar 31, 2026

MINISO Group Holding Limited (MNSO) Reports Q4 Earnings - news.alphastreet.com

Mar 31, 2026